Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00168090 · ClinicalTrials.gov registry record · Phase 4
Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)
A Phase 4 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00168090 is a Phase 4 study that has completed, run by CSL Behring. The registered enrollment target is 30 participants.
The verdict
NCT00168090, a Phase 4 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.
Interventions
- DRUG Blood coagulation Factor VIII and vWF, human
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2001-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00168090
The ClinicalTrials.gov registry entry for NCT00168090 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood coagulation Factor VIII and vWF, human is the first listed.
NCT00168090 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00168090 about?
NCT00168090 is a clinical study titled "Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)". The purpose of this study is to test the safety and effectiveness of Humate-P® to prevent bleeding in patients with von Willebrand Disease who are undergoing surgery.
What is the current status of trial NCT00168090?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2001-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00168090?
The interventions under investigation include: Blood coagulation Factor VIII and vWF, human (DRUG).
Who is sponsoring clinical trial NCT00168090?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.